The Second Circuit Court of Appeals has made a significant ruling regarding the liability of manufacturers and retailers of acetaminophen products. The court's decision affects parents and guardians who claim that prenatal exposure to acetaminophen caused their children to develop attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The court's ruling allows these claims to proceed, potentially changing how acetaminophen is marketed and labeled in the future.
The cases, Rutledge v. Walgreen Co. and Phippen v. Walgreen Co., were filed by a group of plaintiffs, including Tiffany Rutledge and Michelle Phippen, who allege that acetaminophen use during pregnancy led to developmental issues in their children. The court's decision, issued on July 13, 2026, comes after the U.S. District Court for the Southern District of New York dismissed the plaintiffs' complaints, citing a lack of admissible expert testimony linking acetaminophen to these disorders.
The plaintiffs in these cases are a mix of parents and guardians who allege that their children were harmed due to prenatal exposure to acetaminophen, the active ingredient in common pain relievers like Tylenol. They argue that the manufacturers failed to provide adequate warnings about the potential risks associated with using acetaminophen during pregnancy. The defendants in these cases include major corporations like Walgreen Co., Walmart Inc., and Johnson & Johnson Consumer Inc., among others.
The appeals arose after the district court excluded the testimony of several expert witnesses who were expected to testify about the potential link between acetaminophen and neurodevelopmental disorders. In the Rutledge case, five experts were excluded, and in Phippen, an additional expert was also excluded. The district court granted summary judgment to the defendants, effectively dismissing the claims.
In its ruling, the Second Circuit Court of Appeals found that the district court had exceeded its discretion in excluding the testimony of certain experts. The court stated, "We conclude that the District Court exceeded its discretion by excluding the expert testimony of Drs. Baccarelli, Hollander, and Pearson." This indicates that the court believes the excluded testimony could have been relevant and helpful in determining whether a causal relationship exists between acetaminophen use and the disorders in question.
The judges involved in the ruling were Circuit Judges Calabresi, Lynch, and Lee. They emphasized that the case is not about determining whether acetaminophen use during pregnancy has adverse effects but rather about the admissibility of expert testimony in court. The court also clarified that it is not making a determination about the general causation of ADHD and ASD but is instead focusing on the rules of evidence regarding expert testimony.
The court's decision has significant implications for the plaintiffs moving forward. It allows them to present their case with the expert testimony that had previously been excluded, which could strengthen their claims against the manufacturers and retailers of acetaminophen. The ruling also highlights the ongoing debate within the scientific community regarding the potential risks associated with prenatal acetaminophen use.
Going forward, this ruling may prompt manufacturers to reconsider their labeling practices and the warnings they provide regarding acetaminophen. The court noted that federal drug labeling laws do not preempt the plaintiffs' failure-to-warn claims, allowing for the possibility of additional warnings related to ADHD and ASD risks. This could lead to changes in how acetaminophen products are marketed to pregnant women and may influence public health guidelines regarding the use of acetaminophen during pregnancy.
The court has vacated the district court's judgment in both cases and remanded them for further proceedings consistent with its opinion. This means that the cases will return to the lower court for further examination, allowing the plaintiffs to present their expert testimony and continue their claims against the defendants.
As the legal proceedings continue, it remains to be seen how the outcomes of these cases will influence public perception and regulatory practices surrounding acetaminophen use during pregnancy. The court's ruling has opened the door for further exploration of the potential risks associated with this widely used medication, which has been a staple for pain relief for many years.
In conclusion, the Second Circuit Court of Appeals' decision to allow the appeals in Rutledge v. Walgreen Co. and Phippen v. Walgreen Co. marks a pivotal moment for parents and guardians claiming harm from prenatal acetaminophen use. The outcome of these cases could lead to significant changes in how acetaminophen is marketed and the warnings provided to consumers, particularly pregnant women.